DNA vaccine
Sponsors
National Institute of Allergy and Infectious Diseases (NIAID), Institut National de la Santé Et de la Recherche Médicale, France, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, National Center for AIDS/STD Control and Prevention, China CDC, University of Wisconsin, Madison
Conditions
AIDSChronic Hepatitis BHIV InfectionsHead and Neck CancerInfluenzaMetastatic Oropharyngeal CarcinomaProstate CancerRecurrent Oropharyngeal Carcinoma
Early Phase 1
Phase 1
Safety and Immune Response to Preventive HIV Immunization With Adenovirus Serotype 5 or 35 Vector
CompletedNCT00801697
Start: 2009-02-28End: 2015-04-30Updated: 2021-10-14
Safety and Immunogenicity of a Naked DNA-based Vaccine Therapy in Patients With Chronic Hepatitis B
CompletedNCT00988767
Start: 2001-02-28End: 2004-10-31Updated: 2025-09-26
Safety Study of HPV DNA Vaccine to Treat Head and Neck Cancer Patients
TerminatedNCT01493154
Start: 2012-04-30End: 2015-10-31Updated: 2018-11-23
Seasonal Influenza DNA Vaccine Prime With Trivalent Inactivated Vaccine (TIV) Boost Compared to TIV Alone
CompletedNCT01498718
Start: 2011-12-31End: 2013-04-30Updated: 2016-03-24
Phase 2
Safety and Immunogenicity Study of AIDS Vaccine (Combined Use of DNA Vaccine and Recombinant Vaccinia Virus Tiantan)
CompletedNCT01705223
Start: 2012-08-31End: 2015-01-31Updated: 2015-05-06
Provenge With or Without pTVG-HP DNA Booster Vaccine in Prostate Cancer
CompletedNCT01706458
Start: 2013-05-20End: 2020-08-13Updated: 2021-06-18
pBI-11 & TA-HPV (With Pembrolizumab as Treatment for Patients w/Advanced, PD-L1 CPS≥1, hrHPV+ Oropharyngeal Cancer
RecruitingNCT05799144
Start: 2023-05-16End: 2028-09-30Target: 54Updated: 2025-10-22